Results 31 to 40 of about 13,727 (197)

Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial [PDF]

, 2016
Background—The prevalence of pre–diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known.
Cardoso, José Silva, Desai, Akshay S., Jhund, Pardeep S., Kristensen, Søren L., Lefkowitz, Martin P., Martinez, Felipe, McMurray, John J.V., Merkely, Bela, Packer, Milton, Preiss, David, Rizkala, Adel R., Rouleau, Jean L., Shi, Victor C., Solomon, Scott D., Squire, Iain, Starling, Randall C., Swedberg, Karl, Zile, Michael R.   +17 more
core   +1 more source

Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits

Acta Pharmaceutica, 2021
Our study evaluates the effects of sacubitril/valsartan (SAC/VAL) in the rabbit model of doxorubicin-induced heart failure. Twenty rabbits (5 per group) were administered with doxorubicin (DOX, 1.5 mg kg−1, i.v.) to induce heart failure.
Yu Chun, Li Donghao, Li Zhongyan, Yu Donghui, Zhai Guijuan   +4 more
doaj   +1 more source

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials

Frontiers in Public Health, 2022
BackgroundSacubitril-valsartan was recommended for heart failure (HF) and proven cost-effective in HF. Recently, sacubitril-valsartan has been recommended to treat hypertension by the Chinese expert consensus. The cost utility of sacubitril-valsartan for
Yake Lou, Ying Yu, Ying Yu, Jinxing Liu, Jing Huang   +4 more
doaj   +1 more source

Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]

, 2017
Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T., Desai, Akshay S., Dickstein, Kenneth, Jhund, Pardeep S., Køber, Lars, McMurray, John J.V., Mogensen, Ulrik M., Packer, Milton, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R.   +11 more
core   +3 more sources

What can we learn from SOCRATES: more questions than answers? [PDF]

, 2017
This editorial refers to ‘Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) Study’, by B ...
Cleland, John G.F., Mueller, Christian
core   +1 more source

Heterogeneous Pd catalysts as emulsifiers in Pickering emulsions for integrated multistep synthesis in flow chemistry [PDF]

, 2018
Within the “Compartmentalised Smart Factory” approach of the ONE-FLOW project the implementation of different catalysts in “compartments” provided by Pickering emulsions and their application in continuous flow is targeted.
Binks, Bernard P., Gonzales-Groom, Renie, Gruber-Woelfler, Heidrun, Hiebler, Katharina, Lichtenegger, Georg J., Maier, Manuel C., Park, Eun Sung   +6 more
core   +1 more source

Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation

International Journal of Cardiology: Heart & Vasculature, 2019
Background: Sacubitril/valsartan has been shown to improve mortality and reduce hospitalizations in patients with heart failure (HF) with reduced ejection fraction (HFrEF).
Geoffrey Bayard, Antoine Da Costa, Romain Pierrard, Cécile Roméyer-Bouchard, Jean Baptiste Guichard, Karl Isaaz   +5 more
doaj   +1 more source

The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study [PDF]

, 2017
Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-
Aichner, Solveig, Albrecht, Diego, Bremerich, Jens, Delles, Christian, Freyhardt, Patrick, Heye, Tobias, Hrabak-Paar, Maja, Janka, Rolf, Keicher, Christian, Khder, Yasser, Langenickel, Thomas, Mayr, Michael, Ott, Christian, Schmieder, Roland E., Wagner, Frank, Yates, Denise   +15 more
core   +1 more source

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Aims: In recent large trials, sacubitril/valsartan demonstrated favorable effects in patients with HF. However, many patients do not achieve the target dose of treatment.
Koichiro Matsumura MD, Takeshi Ijichi MD, Junko Morimoto MD, Kensuke Takabayashi MD, Mitsunori Miho MD, Keisuke Ueno MD, Eijiro Yagi MD, Toru Takase MD, Masafumi Ueno MD, Gaku Nakazawa MD   +9 more
doaj   +1 more source

Monitoring of biomarkers in heart failure. [PDF]

, 2019
The role of biomarkers is increasingly recognized in heart failure (HF) management, for diagnosis, prognostication, and screening of high-risk patients.
Agewall, Agewall, Agewall, Agostoni, Andrew J S Coats, Ather, Bayes-Genis, Bhambhani, Binas, Broch, Demissei, Felker, Giuseppe M C Rosano, Graham, Greene, Hallén, Harjola, Hoedemaker, Ilaria Spoletini, Januzzi, Januzzi, Ky, McCarthy, Michele Senni, Mueller, Nadar, O'Meara, Pareek, Paul, Peacock, Perk, Ponikowski, Rastogi, Salmonson, Sarhene, Sato, Schneider, Shah, Squire, Stenemo, Tamargo, Troughton, Welsh, Xue   +43 more
core   +1 more source